bluebird bio (NASDAQ:BLUE) Price Target Increased to $12.00 by Analysts at Bank of America
bluebird bio (NASDAQ:BLUE – Free Report) had its price objective boosted by Bank of America from $11.00 to $12.00 in a research note issued to investors on Monday morning, Benzinga reports. Bank of America currently has a buy rating on the biotechnology company’s stock. Several other equities analysts also recently issued reports on the stock. […]
More Stories
Voestalpine (OTCMKTS:VLPNY) Shares Down 4.5% – What’s Next?
Voestalpine AG (OTCMKTS:VLPNY – Get Free Report) was down 4.5% during mid-day trading on Wednesday . The company traded as...
Alfa Financial Software (LON:ALFA) Stock Price Down 1.6% – Should You Sell?
Alfa Financial Software Holdings PLC (LON:ALFA – Get Free Report) shares were down 1.6% during trading on Wednesday . The...
Grammer (ETR:GMM) Shares Up 1.4% – Time to Buy?
Grammer AG (ETR:GMM – Get Free Report) shot up 1.4% on Wednesday . The stock traded as high as €5.10...
Bowen Acquisition Corp Adjourns Meeting to Extend Business Combination Deadline
Bowen Acquisition Corp (NASDAQ:BOWNU) recently adjourned a general meeting scheduled for January 7, 2025, to deliberate on extending the deadline...
Arcadis (OTCMKTS:ARCAY) Shares Down 4.7% – Here’s What Happened
Arcadis NV (OTCMKTS:ARCAY – Get Free Report)’s share price dropped 4.7% on Friday . The company traded as low as...
ENDRA Life Sciences (NASDAQ:NDRA) Trading Down 0.3% – What’s Next?
ENDRA Life Sciences Inc. (NASDAQ:NDRA – Get Free Report) was down 0.3% during mid-day trading on Friday . The company...